The Scan­gos lega­cy: A block­buster MS record with lin­ger­ing doubts about the pipeline

Six years ago, George Scan­gos was re­cruit­ed to head a turn­around team at what was billed as a trou­bled Bio­gen. And it wasn’t long be­fore a big ap­proval for a new mul­ti­ple scle­ro­sis block­buster trig­gered a round of ap­plause—and a bull­ish surge in the com­pa­ny’s stock price—that last­ed for years.

To­day, Scan­gos says his time is up at Bio­gen, well af­ter the ap­plause pe­tered out last year and the mar­ket be­gan to grow rest­less over the CEO’s less suc­cess­ful sec­ond act in a bear­ish mar­ket. In the next few months, he’ll step aside, once his suc­ces­sor can be found to helm the in­flu­en­tial Big Biotech, an in­sti­tu­tion­al land­mark in­side the Boston/Cam­bridge hub.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER